Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG)
Rosetta Genomics has had a great week in the market. First, their stocks climbed following news of a big acquisition, and today, they’re seeing more upward movement following news of a patent allowance. Today, we’ll take a look at the patent allowance announcement, how ROSG reacted in the market, and what we can expect from the company moving forward.
ROSG Climbs On Cancer Origin Patent Allowance
Earlier today, Rosetta Genomics announced that they’ve received a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.” The company can now claim patents with regards to the method they use for identifying a tissue of origin within a cancer sample. For more details on the patent allowance, click here!
How Rosetta Genomics Stock Reacted To The News
Any time a company announces that they’ve received a Notice of Allowance for a U.S. patent, we can expect to see great things in the market; and that’s exactly what we’ve seen. In morning trading, the stock was up by more than 17%. However, as we normally see in these situations, the stock climbed, corrected, and now it is back to stable growth. Currently (11:52), ROSG is trading at $3.96 per share after a gain of 7.03% so far today.
What We Can Expect Moving Forward
When it comes to Rosetta Genomics, I’m a big fan of the stock. The company is making big moves at the moment with the acquisition of PersonalizeDX. Then, the U.S. patent allowance adds icing to the already sweet cake! All in all, I think this one’s set for big things in the long run!
What Do You Think?
Where do you think ROSG is headed and why? Let us know in the comments below!